Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

This is more de-risking than de-risking-to-zero: finishing enrollment improves confidence in execution, but the stock still trades almost entirely on the shape of the blinded data, not on operational milestones. For a clinical-stage name with no revenue cushion, the key variable is whether the Phase 3 signal sustains enough placebo-adjusted efficacy to justify a premium multiple; if it does not, prior enthusiasm will compress quickly because there is no commercial franchise to absorb disappointment.

The competitive read-through is less about direct overlap with existing adjunctive antidepressants and more about validating a clinic-administered, intermittent treatment category. That is incrementally positive for interventional psychiatry broadly, but it is also a reminder that incumbents with scaled distribution and reimbursement pathways will keep most of the economic value unless a new entrant shows clearly better durability or simpler logistics. If HLP003 works, the second-order winners are the clinic infrastructure, specialty pharmacy, and payer-access ecosystem; the losers are oral adjunctive therapies and any late-stage psychedelic peers that cannot show cleaner administration or lower burden.

The biggest near-term risk is not enrollment, it is effect-size fade versus the company’s Phase 2 narrative, which is a common failure mode in MDD. The market should also price in financing risk: a clean run to Q4 2026 does not eliminate dilution if runway is tight, and any capital raise into a pre-data window would cap upside. Over 6-18 months, the real falsifier is either a weak primary endpoint or a 12-week durability readout that fails to expand the opportunity beyond a niche adjunctive use case.